Inflammatory bowel disease with growth hormone deficiency in adolescents: an analysis of 4 cases and literature review.
- Author:
You-You LUO
1
;
Jin-Gan LOU
;
Jin-Dan YU
;
Jie CHEN
Author Information
1. Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310051, China. hzcjie@zju.edu.cn.
- Publication Type:Case Reports
- MeSH:
Adolescent;
Child;
Colitis, Ulcerative;
Crohn Disease;
Female;
Growth Hormone;
Humans;
Inflammatory Bowel Diseases;
Infliximab;
Male
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(1):33-37
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a chronic recurrent non-specific inflammatory disease in the intestinal tract. About 10%-56% of children with Crohn's disease and about 10% of children with ulcerative colitis have growth retardation. This study reports four adolescents with IBD and growth hormone deficiency who were diagnosed with Crohn's disease. There were three boys and one girl, with an age of 11.0-13.9 years and a disease duration of 11-85 months at diagnosis. The four patients had the involvement of the small intestine only, the colon only, both the small intestine and the upper gastrointestinal tract, and both the small intestine and the colon respectively. The pediatric Crohn's disease activity index ranged from 27.5 to 45 points. All four patients had a height-for-age Z-score (HAZ) of <-2, and the growth hormone provocative test suggested growth hormone deficiency. Of all four patients, two received recombinant human growth hormone combined with infliximab, one received infliximab only, and one received recombinant human growth hormone combined with mercaptopurine. All four patients had an improvement in HAZ after treatment.
